{
    "id": 2093,
    "name": "vulvar melanoma",
    "source": "DOID",
    "definition": "A vulva cancer that has_material_basis in melanocytes. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514586/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:2093",
    "evidence": [
        {
            "id": 8614,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, with reduction of tumor mass by 35% at 12 weeks (PMID: 20372153).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2093,
                "name": "vulvar melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6700,
                    "pubMedId": 20372153,
                    "title": "Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20372153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}